Literature DB >> 15210765

Lymphomagenesis, hydronephrosis, and autoantibodies result from dysregulation of IL-9 and are differentially dependent on Th2 cytokines.

Angus J Lauder1, Helen E Jolin, Philippa Smith, José G van den Berg, Alison Jones, William Wisden, Kenneth G C Smith, Ayan Dasvarma, Padraic G Fallon, Andrew N J McKenzie.   

Abstract

Interleukin-9 is an immunoregulatory cytokine implicated in the development of asthma and allergy. To investigate the role of IL-9 in vivo, we have generated transgenic mice in which IL-9 is expressed from its own promoter. Strikingly, overexpression of IL-9 resulted in premature mortality associated with a complex phenotype characterized by the development of autoantibodies, hydronephrosis, and T cell lymphoma. By intercrossing IL-9 transgenic mice with a panel of Th2 cytokine-deficient mice, we demonstrate that these disorders represent distinct phenotypes that can be dissociated by their differential dependence on Th2 cytokines. Autoantibody production was ablated in IL-9 transgenic animals with a combined absence of IL-4, IL-5, and IL-13, coincident with a reduction in peritoneal B-1 cells. Hydronephrosis arose in 75% of IL-9 transgenic animals and was dependent on the presence of IL-4 and IL-13. In contrast, T cell lymphomas developed independently of the other Th2 cytokines, with the generation of rapidly proliferating CD8(+) or CD4(+)CD8(+) T cell clones that arose in the thymus before infiltrating both lymphoid and nonlymphoid tissues. Our data highlight potentially important new roles for IL-9, through its regulation of downstream Th2 effector cytokines, in autoantibody production and in hydronephrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210765     DOI: 10.4049/jimmunol.173.1.113

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Genetic and developmental basis for urinary tract obstruction.

Authors:  Feng Chen
Journal:  Pediatr Nephrol       Date:  2008-12-16       Impact factor: 3.714

2.  Decreased frequency of circulating Th9 cells in patients with chronic hepatitis B infection.

Authors:  Meilan Cui; Ying Lv; Jianhua Lu; Wei Zhang; Yuanyuan Duan; Yan Huang; Lei Yang; Man Li; Wenxuan Liu; Dianwu Liu; Huimin Yan
Journal:  J Clin Lab Anal       Date:  2017-05-08       Impact factor: 2.352

Review 3.  A brief history of IL-9.

Authors:  Ritobrata Goswami; Mark H Kaplan
Journal:  J Immunol       Date:  2011-03-15       Impact factor: 5.422

4.  CX3CR1+ Macrophages and CD8+ T Cells Control Intestinal IgA Production.

Authors:  Young-In Kim; Joo-Hye Song; Hyun-Jeong Ko; Mi-Na Kweon; Chang-Yuil Kang; Hans-Christian Reinecker; Sun-Young Chang
Journal:  J Immunol       Date:  2018-07-09       Impact factor: 5.422

5.  Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia.

Authors:  Na Chen; Kang Lu; Peipei Li; Xiao Lv; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

6.  Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice.

Authors:  Taku Okazaki; Yumi Otaka; Jian Wang; Hiroshi Hiai; Toshiyuki Takai; Jeffrey V Ravetch; Tasuku Honjo
Journal:  J Exp Med       Date:  2005-12-13       Impact factor: 14.307

7.  Developmental pathology of congenital kidney and urinary tract anomalies.

Authors:  Sanjay Jain; Feng Chen
Journal:  Clin Kidney J       Date:  2018-12-01

Review 8.  Interactions between cytokines, congenital anomalies of kidney and urinary tract and chronic kidney disease.

Authors:  Ana Cristina Simões e Silva; Flávia Cordeiro Valério; Mariana Affonso Vasconcelos; Débora Marques Miranda; Eduardo Araújo Oliveira
Journal:  Clin Dev Immunol       Date:  2013-08-26

9.  Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.

Authors:  Andra S Martinikova; Monika Burocziova; Miroslav Stoyanov; Libor Macurek
Journal:  Cells       Date:  2020-09-10       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.